We studied the presence of drug-dependent antibodies (D-DAbs) in 53 patients with AIDS who developed immune hemolytic anemia (IHA). We examined sera and eluates for the presence of D-DAbs. Drug antibodies were detected in 43.4 percent (23/53) of the patients with IHA. Antibodies to more than one drug were detected in 60.8 percent (14/23) of patients with drug-induced IHA (D-IHA). The DAT was positive by RBC-bound IgG in eight patients, RBC-bound IgG/C3d in nine, IgG/IgA in three, IgG/IgA/C3d in two, and one patient had RBC-bound C3d only. No drug-independent antibodies were detected. Our study demonstrates that patients with AIDS commonly develop D-DAbs. D-IHA should be included in the differential diagnosis of a falling Hb in AIDS patients receiving drugs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors.
Front Immunol
January 2025
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Article Synopsis
- This study tested rituximab (RTX) on patients with primary membranous nephropathy (PMN) who were dependent on calmodulin inhibitors (CNIs) and not fully in remission.
- Among 36 patients, those who were drug-dependent showed a significant reduction in proteinuria and improved remission rates after 12 months of RTX therapy, with complete remission increasing from 10% to 70%.
- The results indicated that RTX not only helped patients overcome CNI dependency but also led to significant immunological improvements while minimizing the risks of adverse effects.
Ceftriaxone-induced thrombocytopenia during tuberculosis treatment: a case report.
Eur J Hosp Pharm
September 2024
Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
Article Synopsis
- A patient with miliary tuberculosis was diagnosed with drug-induced immune thrombocytopenia (DITP) caused by ceftriaxone, contrary to the initial assumption that it was due to the tuberculosis drugs.
- Identifying the specific drug causing DITP is crucial to ensure continuation of essential tuberculosis treatment without unnecessary changes.
- When multiple medications are involved, additional testing for drug-dependent platelet antibodies may be needed to make an informed decision about treatment adjustments.
A systematic review of allometric scaling exponents for IgG mAbs.
Xenobiotica
September 2024
DMPK Modelling, GSK, Stevenage, UK.
Increasing complexity of mAbs in development creates challenges in predicting human pharmacokinetic (PK) parameters from preclinical data. The aim of this analysis was to identify optimal allometric scaling exponents.Data were extracted from literature to create a central database (currently the largest available published database) of two-compartment model parameters for mAbs ( = 59) in cynomolgus monkey (CM) and human.
View Article and Find Full Text PDFCase report: Decreased hemoglobin and multiple organ failure caused by ceftizoxime-induced immune hemolytic anemia in a Chinese patient with malignant rectal cancer.
Front Immunol
May 2024
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious condition, with an estimated incidence of one in 100,000 cases, associated with various antibiotics. This study reports on a case of ceftizoxime-induced hemolysis observed in a patient in China.
Case Description: A Chinese patient diagnosed with malignant rectal cancer underwent antimicrobial therapy after laparoscopic partial recto-sigmoid resection (L-Dixon).
Tirofiban-induced thrombocytopenia.
Ann Med
December 2023
Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycine-aspartic acid (RGD) recognition site of GP IIb/IIIa to prevent platelet aggregation. It reduces the incidence of thrombotic cardiovascular events in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Although generally considered safe, tirofiban has been reported to be associated with thrombocytopenia in several case reports and clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!